ABVC BIOPHARMA, INC. — SEC Form D Filing
ABVC BIOPHARMA, INC. filed an SEC Form D on November 10, 2026, reporting $3.39M raised in Biotechnology.
Form D filing details
- Filing
- SEC Form D
- Filing date
- November 10, 2026
- Amount reported
- $3.39M
- Round stage
- Series B+
- Industry
- Biotechnology
- Website
- https://abvcbiopharma.com/
What the company does
Securities: Debt. Exemption: Rule 506(b). Incorporated: NEVADA
Problem
Patients face difficult-to-treat conditions across central nervous system disorders (such as major depressive disorder and adult ADHD), diverse cancers, and eye conditions requiring vitreoretinal surgery.
Solution
ABVC BioPharma develops botanical-derived therapeutic candidates—including PDC-1421-based treatments for depression and ADHD—as well as medical technologies like Vitargus, a biodegradable hydrogel vitreous substitute for eye surgery.
Why now
Growing regulatory and clinical frameworks now allow standardized botanical compounds and advanced hydrogel biomaterials to pass rigorous clinical trial benchmarks.
Verdict
Investors funded this round because a sub-four-million-dollar check offered cheap optionality on late-stage phase transitions across both CNS and ophthalmology, not because they bought into botanical extraction as a coherent platform strategy. Underwriting this meant betting that at least one disparate asset could produce partnering data before the balance sheet evaporated. Upside was strictly capped by the conglomerate structure, which split scarce capital across unrelated modalities and signaled to institutional syndicates that the company lacked the conviction to focus on a single lead program.
Source: SEC EDGAR Form D filing